Red Tree Ventures

redtreevc.com

VCMatch tracks Red Tree Ventures as an investor focused on Biotech, Medtech, and Pharma companies, Pre-Seed and Seed rounds, and West Coast, United States, San Diego, and San Francisco Bay Area markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Pre-Seed, Seed, Series A, Series B, Series C

Focus Areas

Biotech, Medtech, Pharma

Geography

West Coast, United States, San Diego, and San Francisco Bay Area

Investment Thesis

Red Tree is a science-first, West Coast–centered life science investor that targets early-stage, translational therapeutics company creation and financing. Their approach is built around sourcing “innovation emerging” from premier West Coast academic and research institutions and advancing breakthrough science toward clinical and commercial impact.

They emphasize hands-on partnership: acting as lead or co-lead investors, taking board seats, and providing first institutional capital to many companies (seed / Series A) to translate academic discovery into “world-class life science companies” that “transform patient lives.”

Is Red Tree Ventures right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Red Tree Ventures is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in Biotech, Medtech, and Pharma, especially across West Coast, United States, San Diego, and San Francisco Bay Area.

Focus statement

“We focus primarily on entrepreneurs developing first-in-class and/or best-in-class therapeutics addressing significant unmet needs in the areas of oncology, neurology, and immunology.” The firm is "West Coast-centric, early stage-biased," primarily targeting seed, preclinical and early clinical-stage opportunities and selectively backing transformative medical devices.

Value Add

Deep, curated West Coast network and sourcing: "deep relationships with leading West Coast academic and research institutions" and "unique access to scientific luminaries and serial entrepreneurs."
High-caliber scientific advisory board of West Coast academic thought-leaders (department chairs, division chiefs, institute heads) who are also entrepreneurs and founders of >25 companies.
Company-creation orientation: the firm explicitly seeks to "create and/or invest in life science companies" and provides first institutional capital to ~half of its portfolio.
Hands-on, board-level involvement: the firm "place[s] a high priority on serving as lead or co-lead investor... as well as sitting on the boards of our portfolio companies."
Experienced leadership and track record: founding partners and team (e.g., Heath Lukatch, Jennifer Cochran, Jeremy Caldwell) with decades of investing, company-building and exit experience (including IPOs and acquisitions).
Targeted therapeutic focus (oncology, neurology, immunology) combined with selective device investments, aligning scientific advisory expertise with investment strategy.